Sorry, this activity has expired and is no longer available for CME credit. You may still enjoy the program.
CME Information
Provider Statement: This continuing medical education activity is provided by 
.
Support Statement: This activity is supported by an educational grant from Genentech, Inc.
Target Audience: The intended audience for the activity is neurologists and other health care professionals involved in the treatment of patients with multiple sclerosis.
Learning Objectives: Upon successful completion of this educational activity, participants should be better able to:
- Determine the impact of early versus later treatment start on the progression of multiple sclerosis (MS).
- Apply new clinical trial data on new and emerging disease-modifying therapies for the treatment of progressive MS.
- Assess the role of nonconventional imaging techniques, such as optical coherence tomography and advanced magnetic resonance imaging technologies, in the management of patients with MS.
Activity Chair:
Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY
Faculty:
Guy J. Buckle, MD, MPH
Director of Neuroimaging Research
MS Center at Shepherd Center
Atlanta, GA
Stephen Krieger, MD, FAAN
Associate Professor of Neurology
Icahn School of Medicine at Mount Sinai
New York, NY
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Activity Chair and Faculty report the following relationship(s):
Patricia K. Coyle, MD, FAAN, FANA
Consulting Fee: Accordant, Actelion, Alexion, Bayer, Biogen, Celgene, EMD Serono, Genentech/Roche, Novartis, Sanofi Genzyme, TG Therapeutics
Contracted Research: Actelion, Alkermes, Genentech/Roche, MedDay, NINDS, Novartis
Guy J. Buckle, MD, MPH
Consulting Fee: Alexion, Biogen, Celgene, EMD Serono, Genentech, Novartis, Sanofi Genzyme, Teva
Speakers Bureau: Alexion, Biogen, Celgene, EMD Serono, Genentech, Novartis, Sanofi Genzyme, Teva
Stephen Krieger, MD, FAAN
Consulting Fee: Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, MedDay, Novartis, Teva, TG Therapeutics
Speakers Bureau: Biogen, EMD Serono, Novartis
Reviewer reports the following relationship(s):
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is approved for 1 year from the date of original release, July 25, 2019 to July 24, 2020.
How to Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the CME posttest and the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of 5 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com